Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.83 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.83 |
| ▸ | REN | P00797 | 3/20 | 0.65 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.61 |
| ▸ | ANPEP | P15144 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL1189 | 0.99 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL13232382 | 0.99 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2566771 | 0.99 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL14990505 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21267957 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL3465991 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1585377 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL8898391 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21408200 | 0.98 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL513519 | 0.98 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | AGTR1 3279/4885AGTR2 3547/4885REN 1890/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | AGTR1 1066/4885AGTR2 1175/4885REN 2640/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | AGTR1 1066/4885AGTR2 1175/4885REN 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.